Summary In the present study, we determined the frequency and intensity of MRP protein expression by monoclonal antibody immunohistochemistry in a series of 259 resected invasive primary breast carcinomas, and we evaluated MRP immunoreactivity in relation to patient and tumour characteristics, relapse-free (RFS) and overall survival (OS). The immunostaining was graded on a semiquantitative scale that ranged from (-) to (+++). Overall, 34% of the tumours were positive for anti-MRP antibody: 19% showed weak cytoplasmic staining (+), 14% had clear cytoplasmic staining (++) and only 1 % of the tumours had a strong cytoplasmic as well as membranous staining (+++). MRP expression was not related to patient's age, menopausal status, tumour size, differentiation grade, oestrogen and progesterone receptor level or lymph node involvement. In an exploratory univariate analysis of all patients, only primary tumour size and number of lymph nodes involved were significantly associated with shortened RFS (P < 0.001 and P < 0.001 respectively) and OS (P = 0.02 and P < 0.001 respectively). In Cox univariate analysis for RFS in subgroups of patients stratified by menopausal status, tumour size, nodal status, adjuvant systemic therapy and oestrogen and progesterone receptor status, MRP expression was associated with increased risk for failure in patients with small tumours (Ti), in node-negative patients and in node-positive patients who received adjuvant systemic chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF); the relative hazard rate (RHR) for relapse was increased in the presence of MRP, with RHR values with 95% confidence limits (CL) of 2.8 (1.2-6.9), 2.1 (1.0-4.2) and 2.8 (0.8-9.9) respectively. In analysis for OS, expression of MRP was also associated with increased risk for failure in patients with small tumours (T1) [RHR (95% CL) 2.3 (0.9-6.0)] and in node-positive patients who received adjuvant systemic chemotherapy with CMF [RHR (95% CL) 3.7 (0.8-17.1)] but not in node-negative patients [RHR (95% CL) 1.1 (0.4-2.6)]. In conclusion, our results show that MRP is frequently overexpressed in primary breast cancer and suggest that MRP expression might be of prognostic significance in the subgroups of patients with the more favourable prognosis, i.e. patients with small tumours and nodenegative patients, as well as in the setting of adjuvant systemic chemotherapy. In primary breast cancer, MRP might be related to altered cell biological behaviour, including a more aggressive phenotype, and resistance to adjuvant systemic chemotherapy.
Breast cancer is the most common malignancy among women in the Western world. In patients with operable disease, the axillary lymph node status is one of the most important prognostic factors. Approximately 40-50% of patients have tumour involvement of the axillary nodes with a 10-year survival of less than 50% (Henderson et al, 1989) . Of the node-negative patients, 70% can be cured by surgery or breast-conserving treatment (McGuire and Clark, 1992) . The fact that even 30% of the node-negative patients relapse indicates that in many instances breast cancer at diagnosis is a systemic disease that consequently requires adjuvant systemic therapy with hormones or cytotoxic drugs. The occurrence of drug resistance is one of the main obstacles for successful chemotherapy in breast cancer. In vitro studies have revealed different mechanisms of cytotoxic drug resistance in cancer cells, including energy-dependent extrusion pumps (reviewed in Clynes, 1993; Goldstein and Ozols, 1994) . Two members of the ATP-binding cassette superfamily of transport proteins have been identified, the classical 170-kDa Pgp/MDRI and more recently the 190-kDa MRP, whose overexpression makes cells multidrug resistant (MDR) in vitro against natural product anti-cancer drugs. After the discovery of PgplMDRI as a pump for anti-cancer drugs, it was initially thought that the molecule would play a decisive role in tumour responsiveness to chemotherapy in the majority of patients. However, for the frequently occurring human cancers, including cancers of the lung and breast, a role for PgplMDRI in clinical drug resistance has still not been established unequivocally (Lai et al, 1989; Merkel et al, 1989; Doyle, 1993; Nooter and Sonneveld, 1994; Linn et al, 1995) . The multidrug resistance-associated protein (MRP) gene (Cole et al, 1992 ) encodes a 190-kDa membrane-bound glycoprotein of 1531 amino acids (Cole et al, 1992; Krishnamachary and Center, 1993; Childs and Ling, 1994; Hipfner et al, 1994) . Transfection experiments with different eukaryotic expression vectors containing fulllength complementary DNAs of the MRP gene have shown that MRP confers resistance to a broad range of natural product drugs, among which are anthracyclines, vinca alkaloids and epipodophyllotoxins (Grant et al, 1994; Kruh et al, 1994; Zaman et al, 1994) . As yet, the mode of action by which MRP makes cells MDR is not known. However, the available data suggest that MRP acts both as a plasma membrane outward drug pump and as a pump for drug accumulation in intracytoplasmic vesicles Zaman et al, 1994; Breuninger et al, 1995; Paul et al, 1996) . By both mechanisms, cytoplasmic concentrations of free drug may be reduced to sublethal levels, and in that way MRP would promote cell survival.
The association of MRP with clinical drug resistance has not been elaborated yet, and studies on MRP expression in human cancers have just begun. Expression of MRP has been demonstrated in a variety of solid tumours (Bordow et al, 1994; Thomas et al, 1994; Nooter et al, 1995, 1996a and b; Ota et al, 1995; Endo et al, 1996; Filipits et al, 1996; Kavallaris et al, 1996) and leukaemias (Burger et al, 1994a and b; Schneider et al, 1995) . In a previous study (Nooter et al, 1995) , we determined the expression ofMRP in normal tissues and in about 370 human tumour biopsies using a quantitative RNAase protection assay and immunohistochemistry (IHC). MRP appeared to be ubiquitously expressed at low levels in all normal tissues, including peripheral blood cells, endocrine glands, the lymphoreticular system and the digestive, respiratory and urogenital tract. The human cancers analysed could be divided, based on intensity and frequency of expression, into several MRP expression groups. In that particular study, and in a subsequent study in non-small-cell lung cancer (Nooter et al, 1996a) , RNAase protection assay was compared with IHC for the detection of MRP expression, and we showed that, primarily because of the availability of high-affinity MRP-specific monoclonal antibodies (MAbs) (Flens et al, 1994; MRPm6 and MRPrl) with the MRP-specific monoclonal antibody (MAb) MRPrl as described previously (Nooter et al, 1995; 1996a (Burger et al, 1994a; Flens et al, 1994 enzyme immunoassays (Abbott Laboratories, IL, USA), as described previously (Foekens et al, 1989) .
Statistical analysis
The association of MRP expression with patient and tumour characteristics was tested non-parametrically with the two-sample Wilcoxon rank-sum test for continuous variables (age, ER, PgR) or with the Pearson's X2 test for categorical variables (menopausal status, tumour size, nodal status, differentiation grade, adjuvant treatment). The Cox proportional hazards model was applied for both univariate and multivariate analyses using the associated likelihood ratio test to test for differences. RFS and OS probabilities were calculated by the actuarial method of Kaplan and Meier (1958) . For all tests, a two-sided P-value below 0.05 was considered to be statistically significant.
RESULTS

MRP expression in primary breast cancer
Expression of MRP was determined by IHC with MRPrl on cryostat sections of primary breast cancer specimens, and the expression was correlated with specific patient and tumour characteristics, and RFS and OS. The MRPrl antibody reacted abundantly with the MRP-positive control cell line GLC4/ADR, whereas in the parental cell line GLC4, no staining was observed. The GLC4/ADR cells showed membrane staining as well as cytoplasmic staining, as (Nooter et al, 1995; 1996a (Table 2) . Similarly, age, menopausal status, ER and PgR were not significantly related to RFS and OS in univariate analysis. On the other hand, the size of the primary tumour and the number of lymph nodes involved were significantly associated with a shortened RFS and OS (Table 2 ). In accordance with Cox univariate analysis, multivariate analysis showed that MRP expression was not significantly associated with prognosis. Subsequently, we performed an exploratory Cox regression analysis for RFS and OS in subgroups of patients stratified by menopausal status, tumour size, nodal status, adjuvant systemic therapy, and ER and PgR status (Tables 3 and 4) . For each subgroup, the number of patients positive and negative for MRP are shown. In Tables 3 and 4 , the relative risk for failure expressed as RHR with its 95% CL is given in relation to expression of MRP in the primary tumour (MRP positive vs MRP negative). For MRPnegative tumours, the RHR = 1 by definition. We have not given the P-values as the power of the Cox regression analysis is low when only a limited number of failures and small groups of patients are available. In three subgroups, MRP expression was associated with increased risk for failure. In patients with small tumours (TI), in node-negative patients and in node-positive patients who received adjuvant systemic chemotherapy with CMF, the RHR for relapse was increased in the presence of MRP (Table 3: RHR 2.8, 2.1 and 2.8 respectively). The relationship of MRP to RFS in the subgroup of patients with small tumours (TI) and in node-negative patients is shown in Figure 1 . The numbers of patients at risk are indicated in the figures. In analysis for OS, expression of MRP was also associated with increased risk for failure in patients with small tumours (Ti) and in node-positive patients who received adjuvant systemic chemotherapy with CMF but not in node-negative patients (Table 4: 
DISCUSSION
A large number of cell biological parameters (reviewed in Klijn et al, 1993) , including oncogenes, tumour-suppressor genes, growth factor and hormone receptors, and secretory proteins, have been found to influence tumour behaviour with respect to metastatic pattem, cellular differentiation, growth rate and the development of therapy resistance. In the present study, we determined the expression of the drug-resistance MRP gene in a series of more than 250 primary breast cancer specimens, and we evaluated its expression in relation to patient and tumour characteristics, and RFS and OS. By IHC using the high-affinity MAb MRPrl (Flens et al, 1994) , expression of MRP protein was found in about 30% of primary breast carcinomas. The majority of these samples had weak to moderate MRP expression levels, and only 1% of the primary breast cancer specimens had strong MRP staining in the cytoplasm and on the cell membrane. These results are in agreement with preliminary data from our own group (Nooter et al, 1995) and those of others (Filipits et al, 1996) . In a previous study (Nooter et al, 1995) , we found expression of MRP mRNA, as determined by RNAase protection assay, in approximately 80% of breast cancer specimens. In the same study, MRP protein was found to be expressed in 2 of 11 breast cancer specimens only. In a recent paper by the group of Pirker (Filipits et al, 1996) , all primary breast cancer specimens expressed MRP mRNA as determined by reverse transcriptase-polymerase chain reaction. By IHC with two MRP-specific MAbs (QCRL-1 and QCRL-3) developed by the group of Cole and Deeley (Hipfner et al, 1994) , strong staining was observed in 24% and weak staining in the remaining 76% of the breast cancer specimens (Filipits et al, 1996) . From these studies it might be concluded that MRP mRNA is expressed at a very low level in most breast cancer specimens and that a smaller part (20-40%) of the specimens have elevated levels of MRP. The ubiquitous, low-level expression of MRP mRNA in breast cancer is in concordance with the MRP expression in the normal, unaffected mammary gland (Flens et al, 1996) . MRP was detected at the protein level in different types of normal epithelial cells from the bronchus, digestive tract and adrenal cortex (Flens et al, 1996) , suggesting that MRP may have an excretory function in protecting the organism against xenobiotics. In the mammary gland, the lobules were negative for MRP, while in the lactiferous ducts some weak, focal expression could be detected.
In (Weinstein et al, 1991) , breast (Linn et al, 1995) and renal cell carcinomas (Tobe et al, 1995) . For these cancers, evidence was provided that Pgp expression and tumour invasiveness may be linked. However, the apparent association between Pgp expression and a more malignant phenotype is not a universal phenomenon. In childhood rhabdomyosarcoma, Pgp expression at diagnosis, in fact, appeared to be associated with better RFS and OS (Kuttesch et al, 1996 (Bordow et al, 1994; Kuss et al, 1994; Ota et al, 1995) suggest, based on historical data, a correlation between clinical response to chemotherapy and level of MRP expression. One study (Kuss et al, 1994) reported the absence of MRP expression as a result of chromosomal aberrations in a subgroup of drug-sensitive (daunorubicin and ara-C) AML (M4), with inversion of chromosome 16. Another study (Bordow et al, 1994) suggested the complementary correlation of increased MRP expression in aggressive, notorious drug-resistant neuroblastomas with N-myc oncogene amplification. Expression of the MRP gene was correlated with amplification and overexpression of the N-myc oncogene, especially in advanced-stage tumours that tend to be particularly aggressive and unresponsive to chemotherapy. In squamous cell carcinoma of the lung, the prognoses of patients with MRP expression were significantly worse than those of patients without MRP expression (Ota et al, 1995) . In the present study, MRP expression in adjuvant CMF-treated, nodepositive patients was associated with duration of RFS and OS, suggesting that MRP expression might encode drug resistance in vivo against adjuvant systemic chemotherapy. In this respect, it is of note that as yet none of the drugs in the CMF regimen has been shown to be a substrate for MRP. In particular, in analysis for OS, the absence of MRP expression was associated with a prolonged survival. Of these node-positive CMF-treated patients, 92% were still alive after 5 years compared with 57% for the patients with a positive MRP score. Although very suggestive, these data are based on small patient numbers and should therefore be considered carefully; they should rather be used as indication for future studies. In conclusion, our results show that MRP is frequently overexpressed in primary breast cancer and suggest that MRP expression might be of prognostic significance in the subgroups of patients with a more favourable prognosis, i.e. patients with small tumours and node-negative patients, as well as in the setting of adjuvant systemic chemotherapy. Further studies with larger patient populations should confirm whether in primary breast cancer MRP is related to altered cell biological behaviour, including a more aggressive phenotype, and resistance to adjuvant systemic chemotherapy.
